TORONTO, August 3, 2022 – The Northwest Territories and Non-Insured Health Benefits (NIHB) have completed an agreement with the manufacturer of Trikafta to fund the revolutionary cystic fibrosis (CF) drug for people aged six years and older, effective July 29, 2022.
Read MoreNews
All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.
Cystic Fibrosis Canada calls on remaining provinces and territories to fund Trikafta for children six and up and lift any overly-restrictive access criteria
Read MoreAll other provinces and territories called on to fund Trikafta for children six and up and lift any overly-restrictive access criteria
Read MoreAll other provinces and territories called on to fund Trikafta for children six and up and lift any overly-restrictive access criteria
Read MoreAll other provinces and territories called on to fund Trikafta for children six and up and lift any overly-restrictive access criteria
Read MoreReview body issues milestone recommendation for the life-changing drug, removes restrictive start criterion
Read MoreCystic Fibrosis Canada calls on public and private payers to immediately fund Trikafta for all who can benefit.
Read MoreSix Research Grants, an Early Career Investigator Award and three Research Fellowships focus on CF Community’s Health Needs
Read MoreCystic Fibrosis Canada asks participants to go #FurtherTogether for Canadians with cystic fibrosis
Read More